Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | UBE2T | Q9NPD8 | 1/20 | 0.61 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.57 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 3/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrogen Sulfide SCHEMBL23045115 | 0.98 | UBE2T (0.59) | UBE2TASIC3SMN1; SMN2ALOX15HTT | |
| Iodide SCHEMBL9106979 | 0.98 | UBE2T (0.59) | UBE2TASIC3SMN1; SMN2ALOX15HTT | |
| SCHEMBL2034241 | 0.89 | SMN1; SMN2 (0.62) | UBE2TASIC3SMN1; SMN2ALOX15HTT | |
| SCHEMBL19372016 | 0.88 | UBE2T (0.70) | UBE2TASIC3SMN1; SMN2ALOX15HTT | |
| SCHEMBL31173766 | 0.87 | ALOX15 (0.60) | UBE2TASIC3SMN1; SMN2ALOX15HTT | |
| SCHEMBL175532 | 0.87 | ALOX15 (0.60) | UBE2TASIC3SMN1; SMN2ALOX15HTT | |
| Benzene SCHEMBL28273759 | 0.87 | SMN1; SMN2 (0.65) | UBE2TASIC3SMN1; SMN2ALOX15HTT | |
| SCHEMBL11596488 | 0.86 | ALOX15 (0.59) | UBE2TASIC3SMN1; SMN2ALOX15HTT | |
| SCHEMBL9155744 | 0.86 | ALOX15 (0.59) | UBE2TASIC3SMN1; SMN2ALOX15HTT | |
| Hydrochloric Acid SCHEMBL3192243 | 0.86 | ALOX15 (0.59) | UBE2TASIC3SMN1; SMN2ALOX15HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119707859-A | Para-substituted heptamethine quinone cyanine dye and synthetic method and application thereof | 大连理工大学 | 2025-03-28 | — | — | CN | claimed |
| CN-113980583-A | Ultraviolet curing composition glue based on pyridine substituted acrylate compound and using method and application thereof | 西安思摩威新材料有限公司 | 2022-01-28 | — | — | CN | claimed |
| CN-119707859-A | Para-substituted heptamethine quinone cyanine dye and synthetic method and application thereof | 大连理工大学 | 2025-03-28 | — | — | CN | disclosed |
| US-20240294821-A1 | CORROSION INHIBITION COMPOSITIONS AND METHODS OF USE IN SOUR ENVIRONMENTS | SAUDI ARABIAN OIL COMPANY (SA) | 2024-09-05 | — | — | US | disclosed |
| CN-117024372-A | Synthesis method of benzothiazoline | 温州大学新材料与产业技术研究院 | 2023-11-10 | — | — | CN | disclosed |
| CN-113980583-B | Ultraviolet light curing composition glue based on pyridine substituted acrylate compound, and use method and application thereof | 西安思摩威新材料有限公司 | 2023-09-08 | — | — | CN | disclosed |
| CN-115504942-A | Synthesis method of alkyl or acyl substituted benzothiazole derivative | 汕头大学 | 2022-12-23 | — | — | CN | disclosed |
| US-11279733-B2 | Peptide antibiotics | THE UNIVERSITY OF QUEENSLAND (AU) | 2022-03-22 | — | — | US | disclosed |
| CN-113980583-A | Ultraviolet curing composition glue based on pyridine substituted acrylate compound and using method and application thereof | 西安思摩威新材料有限公司 | 2022-01-28 | — | — | CN | disclosed |
| CN-113461617-A | Method for preparing N-heterocycle through visible light mediated dehydrogenation | 石河子大学 | 2021-10-01 | — | — | CN | disclosed |
| EP-3835322-A2 | ANTI-B7-H3 ANTIBODIES AND ANTIBODY DRUG CONJUGATES | AbbVie Inc. (US) | 2021-06-16 | — | — | EP | disclosed |
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | GILEAD SCIENCES, INC. | 2012-01-12 | — | — | US | disclosed |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | GALENEA CORPORATION | 2011-06-16 | — | — | US | disclosed |
| WO-2011058149-A1 | TRICYCLIC PYRAZOL AMINE DERIVATIVES | MERCK SERONO S.A. (CH) | 2011-05-19 | — | — | WO | disclosed |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-02-05 | — | — | US | disclosed |
| US-7453002-B2 | thrombotic or an inflammatory disorders; improved factor XIa and/or plasma kallikrein inhibitory activity and selectivity, dosage requirment, costs or feasibility, side effect reduction; 4-(aminomethyl)-N-[2-phenyl-1-(4-pyridin-2-yl-1H-imidazol-2-yl)ethyl]-trans-cyclohexanecarboxamide | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-18 | — | — | US | disclosed |
| US-4708810-A | LUBRICANT ADDITIVE | CASTROL LIMITED (GB) | 1987-11-24 | — | — | US | disclosed |
| EP-0022326-B1 | PROCESS FOR CHEMICALLY REMOVING THE ACYL SIDECHAIN FROM CEPHALOSPORINS AND PENICILLINS | E.R. Squibb & Sons, Inc. (US) | 1983-01-19 | — | — | EP | disclosed |
| US-4252973-A | Process for chemically removing the acyl sidechain from cephalosporins and penicillins | E. R. SQUIBB & SONS, INC. (US) | 1981-02-24 | — | — | US | disclosed |
| EP-0022326-A1 | Process for chemically removing the acyl sidechain from cephalosporins and penicillins | E.R. Squibb & Sons, Inc. (US) | 1981-01-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120010192-A1 | Fused Heterocyclic Compounds as Ion Channel Modulators | KCNJ2, KCNH2, CACNA1E | UBE2T 4167/4885ASIC3 150/4885SMN1; SMN2 1093/4885 |
| US-20110144090-A1 | COMPOUNDS AND METHODS OF USE THEREOF | AANAT, HNMT, INMT | UBE2T 3854/4885ASIC3 4370/4885SMN1; SMN2 1404/4885 |
| US-11279733-B2 | Peptide antibiotics | NGLY1, VIP, PEPD | UBE2T 3517/4885ASIC3 2928/4885SMN1; SMN2 4207/4885 |
| US-20090036438-A1 | FIVE-MEMBERED HETEROCYCLES USEFUL AS SERINE PROTEASE INHIBITORS | F12, F11, F5 | UBE2T 3012/4885ASIC3 1569/4885SMN1; SMN2 4322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.